Justin Zamirowski - May 16, 2022 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role: Chief Commercial Officer
Signature: /s/ Mark Heinen, Attorney-in-Fact
Stock symbol: BTTX
Transactions as of: May 16, 2022
Transactions value $: $17,618
Form type: 4
Date filed: 5/18/2022, 05:12 PM
Previous filing: Apr 4, 2022
Next filing: Jun 1, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Ownership	Footnotes
transaction	BTTX	Common Stock	Options Exercise	$17.6 K	+35.2 K		$0.50	35.2 K	May 16, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BTTX	Stock Option (Right to Buy)	Options Exercise	$0	-35.2 K	-43.75%	$0.00	45.3 K	May 16, 2022	Common Stock	35.2 K	$0.50	Direct	F1

Explanation of Responses:

Id	Content
F1	The Assumed Option (as defined in the Agreement and Plan of Merger, dated April 6, 2021, as amended, by and among Mountain Crest Acquisition Corp. II, MCAD Merger Sub Inc. and Better Therapeutics, Inc.) vests as to 1/4th of the shares subject to the Assumed Option on July 27, 2021 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The Assumed Option was granted on August 14, 2020.

Content

The Assumed Option (as defined in the Agreement and Plan of Merger, dated April 6, 2021, as amended, by and among Mountain Crest Acquisition Corp. II, MCAD Merger Sub Inc. and Better Therapeutics, Inc.) vests as to 1/4th of the shares subject to the Assumed Option on July 27, 2021 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The Assumed Option was granted on August 14, 2020.